Patients with psoriasis generally prefer the standard of care over teledermatology, but certain attributes change patient preferences.

Symptoms, lesion locations, and morphology are among the features clinicians may use to distinguish hand eczema from hand psoriasis in patients.

Natasha Nettles is a strong woman. She’s a mom, a makeup artist, and she also happens to have psoriasis. But she doesn’t let this one part of her life take her down. She doesn’t let it ...

Air pollution significantly contributes to and worsens various dermatologic conditions through oxidative stress, inflammation ...

Scalp care is essential for hair health, the same way good soil is ... She also recommends it for those dealing with psoriasis and seborrheic dermatitis on the scalp. When it comes to scalp ...

Scalp psoriasis poses unique challenges for people of color, including misdiagnosis, treatment access barriers, and lack of representation in medical education. Dr. Mona Shahriari, the senior editor ...

Now, a study from Michel Gilliet's laboratory shows that the antimicrobial peptide LL37 is responsible for activation of pDCs in psoriasis. Knowing that pDCs are activated in psoriasis ...

However, some Medicare Advantage plans may cover wigs for people living with cancer and losing hair from chemotherapy. The extent of hair loss from cancer treatments like chemotherapy varies among ...

Results showed 66% of patients treated with icotrokinra achieved an ss-IGA score of 0/1 and 77% achieved a sPGA-G score of 0/1, compared with 11% and 21% receiving placebo, respectively, at week 16.

Psoriasis is a sign that your immune system is not working properly. Proactively managing and making lifestyle changes to maintain a strong immune system may help reduce psoriasis flare-ups. While ...

U.S. and European health regulators are warning the public of possible health risks linked to finasteride, a popular hair-loss drug. The European Medicines Agency issued an alert on Thursday ...

66% of patients with scalp psoriasis achieved a scalp-specific Investigator's Global Assessment (ss-IGA) c score of 0/1 compared to 11% receiving placebo (P<0.001) at 16 weeks.